Gene therapy company Lexeo Therapeutics nabs $100m Series B

Lexeo Therapeutics, a clinical-stage gene therapy company, has secured $100 million in Series B financing.

9 September 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles